35 thousand participants in the experiments

"Curvac" begins the third phase of trials for the "Corona" vaccine

Curvac will produce 405 million doses for Europe.

Archives

The German company, Curvac, for vital medicines has taken a new step on the road towards obtaining approval for its emerging coronavirus (Covid-19) vaccine, and the company announced yesterday the start of the third phase of clinical trials necessary to obtain approval with the participation of more than 35 thousand participant.

The company said, in a statement, that it expects the first results of the third phase tests to appear at the end of the first quarter of 2021. After the start of the third phase, the president of the company, Franz-Werner Haas, spoke about a "qualitative leap in the development of the company's candidate vaccine."

In the first stage, the vaccine was given to 250 healthy volunteers, between the ages of 18 and 60, to test their tolerance and ability to immunize.

In the second phase, 690 volunteers have been vaccinated in treatment centers in Peru and Panama since late summer.

The third stage aims to prove the effectiveness and safety of the new so-called MRNA vaccine against the virus.

Like the vaccine developed by the German company "Biontec" and "Pfizer" of America, "Curvac" is working on an active substance called "MRNA", a type of intermediate molecule that includes instructions for producing proteins.

The "Curvac" researchers provided "MRNA" with instructions for the production of the emerging corona virus protein, for use in the anti-virus vaccine.

After vaccination, human cells form this protein, which the body recognizes as a foreign particle, so that the body forms antibodies and other immune cells against it.

And unlike conventional vaccines, where the active ingredient is grown using viruses for several months, and then injected into a weak form, the MRNA vaccine does not use live pathogens and cell cultures, and this aims to reduce the potential risks.

The European Commission had signed a contract with "CureVac", to purchase 405 million doses of vaccine.

Follow our latest local and sports news, and the latest political and economic developments via Google news